line_item,period,value,symbol
Tax Effect Of Unusual Items,2025-03-31 00:00:00,0.0,AARTIDRUGS.NS
Tax Rate For Calcs,2025-03-31 00:00:00,0.206214,AARTIDRUGS.NS
Normalized EBITDA,2025-03-31 00:00:00,3034200000.0,AARTIDRUGS.NS
Total Unusual Items,2025-03-31 00:00:00,0.0,AARTIDRUGS.NS
Total Unusual Items Excluding Goodwill,2025-03-31 00:00:00,0.0,AARTIDRUGS.NS
Net Income From Continuing Operation Net Minority Interest,2025-03-31 00:00:00,1681600000.0,AARTIDRUGS.NS
Reconciled Depreciation,2025-03-31 00:00:00,557800000.0,AARTIDRUGS.NS
Reconciled Cost Of Revenue,2025-03-31 00:00:00,15421000000.0,AARTIDRUGS.NS
EBITDA,2025-03-31 00:00:00,3034200000.0,AARTIDRUGS.NS
EBIT,2025-03-31 00:00:00,2476400000.0,AARTIDRUGS.NS
Net Interest Income,2025-03-31 00:00:00,-358700000.0,AARTIDRUGS.NS
Interest Expense,2025-03-31 00:00:00,358700000.0,AARTIDRUGS.NS
Interest Income,2025-03-31 00:00:00,,AARTIDRUGS.NS
Normalized Income,2025-03-31 00:00:00,1681600000.0,AARTIDRUGS.NS
Net Income From Continuing And Discontinued Operation,2025-03-31 00:00:00,1681600000.0,AARTIDRUGS.NS
Total Expenses,2025-03-31 00:00:00,21557500000.0,AARTIDRUGS.NS
Rent Expense Supplemental,2025-03-31 00:00:00,,AARTIDRUGS.NS
Diluted Average Shares,2025-03-31 00:00:00,91270000.0,AARTIDRUGS.NS
Basic Average Shares,2025-03-31 00:00:00,91270000.0,AARTIDRUGS.NS
Diluted EPS,2025-03-31 00:00:00,18.35,AARTIDRUGS.NS
Basic EPS,2025-03-31 00:00:00,18.35,AARTIDRUGS.NS
Diluted NI Availto Com Stockholders,2025-03-31 00:00:00,1681600000.0,AARTIDRUGS.NS
Net Income Common Stockholders,2025-03-31 00:00:00,1681600000.0,AARTIDRUGS.NS
Otherunder Preferred Stock Dividend,2025-03-31 00:00:00,0.0,AARTIDRUGS.NS
Net Income,2025-03-31 00:00:00,1681600000.0,AARTIDRUGS.NS
Minority Interests,2025-03-31 00:00:00,615000.0,AARTIDRUGS.NS
Net Income Including Noncontrolling Interests,2025-03-31 00:00:00,1681000000.0,AARTIDRUGS.NS
Net Income Continuous Operations,2025-03-31 00:00:00,1681000000.0,AARTIDRUGS.NS
Tax Provision,2025-03-31 00:00:00,436700000.0,AARTIDRUGS.NS
Pretax Income,2025-03-31 00:00:00,2117700000.0,AARTIDRUGS.NS
Other Non Operating Income Expenses,2025-03-31 00:00:00,163600000.0,AARTIDRUGS.NS
Special Income Charges,2025-03-31 00:00:00,0.0,AARTIDRUGS.NS
Other Special Charges,2025-03-31 00:00:00,,AARTIDRUGS.NS
Write Off,2025-03-31 00:00:00,,AARTIDRUGS.NS
Net Non Operating Interest Income Expense,2025-03-31 00:00:00,-358700000.0,AARTIDRUGS.NS
Total Other Finance Cost,2025-03-31 00:00:00,,AARTIDRUGS.NS
Interest Expense Non Operating,2025-03-31 00:00:00,358700000.0,AARTIDRUGS.NS
Interest Income Non Operating,2025-03-31 00:00:00,,AARTIDRUGS.NS
Operating Income,2025-03-31 00:00:00,2312800000.0,AARTIDRUGS.NS
Operating Expense,2025-03-31 00:00:00,6136500000.0,AARTIDRUGS.NS
Other Operating Expenses,2025-03-31 00:00:00,4457700000.0,AARTIDRUGS.NS
Depreciation And Amortization In Income Statement,2025-03-31 00:00:00,557800000.0,AARTIDRUGS.NS
Amortization,2025-03-31 00:00:00,,AARTIDRUGS.NS
Depreciation Income Statement,2025-03-31 00:00:00,557800000.0,AARTIDRUGS.NS
Selling General And Administration,2025-03-31 00:00:00,,AARTIDRUGS.NS
Selling And Marketing Expense,2025-03-31 00:00:00,,AARTIDRUGS.NS
General And Administrative Expense,2025-03-31 00:00:00,,AARTIDRUGS.NS
Gross Profit,2025-03-31 00:00:00,8449300000.0,AARTIDRUGS.NS
Cost Of Revenue,2025-03-31 00:00:00,15421000000.0,AARTIDRUGS.NS
Total Revenue,2025-03-31 00:00:00,23870300000.0,AARTIDRUGS.NS
Operating Revenue,2025-03-31 00:00:00,23870300000.0,AARTIDRUGS.NS
Tax Effect Of Unusual Items,2024-03-31 00:00:00,0.0,AARTIDRUGS.NS
Tax Rate For Calcs,2024-03-31 00:00:00,0.271473,AARTIDRUGS.NS
Normalized EBITDA,2024-03-31 00:00:00,3205000000.0,AARTIDRUGS.NS
Total Unusual Items,2024-03-31 00:00:00,0.0,AARTIDRUGS.NS
Total Unusual Items Excluding Goodwill,2024-03-31 00:00:00,0.0,AARTIDRUGS.NS
Net Income From Continuing Operation Net Minority Interest,2024-03-31 00:00:00,1714200000.0,AARTIDRUGS.NS
Reconciled Depreciation,2024-03-31 00:00:00,514500000.0,AARTIDRUGS.NS
Reconciled Cost Of Revenue,2024-03-31 00:00:00,16777200000.0,AARTIDRUGS.NS
EBITDA,2024-03-31 00:00:00,3205000000.0,AARTIDRUGS.NS
EBIT,2024-03-31 00:00:00,2690500000.0,AARTIDRUGS.NS
Net Interest Income,2024-03-31 00:00:00,-335200000.0,AARTIDRUGS.NS
Interest Expense,2024-03-31 00:00:00,335200000.0,AARTIDRUGS.NS
Interest Income,2024-03-31 00:00:00,24955000.0,AARTIDRUGS.NS
Normalized Income,2024-03-31 00:00:00,1714200000.0,AARTIDRUGS.NS
Net Income From Continuing And Discontinued Operation,2024-03-31 00:00:00,1714200000.0,AARTIDRUGS.NS
Total Expenses,2024-03-31 00:00:00,22635700000.0,AARTIDRUGS.NS
Rent Expense Supplemental,2024-03-31 00:00:00,600000.0,AARTIDRUGS.NS
Diluted Average Shares,2024-03-31 00:00:00,91940000.0,AARTIDRUGS.NS
Basic Average Shares,2024-03-31 00:00:00,91940000.0,AARTIDRUGS.NS
Diluted EPS,2024-03-31 00:00:00,18.56,AARTIDRUGS.NS
Basic EPS,2024-03-31 00:00:00,18.56,AARTIDRUGS.NS
Diluted NI Availto Com Stockholders,2024-03-31 00:00:00,1714200000.0,AARTIDRUGS.NS
Net Income Common Stockholders,2024-03-31 00:00:00,1714200000.0,AARTIDRUGS.NS
Otherunder Preferred Stock Dividend,2024-03-31 00:00:00,0.0,AARTIDRUGS.NS
Net Income,2024-03-31 00:00:00,1714200000.0,AARTIDRUGS.NS
Minority Interests,2024-03-31 00:00:00,-1725000.0,AARTIDRUGS.NS
Net Income Including Noncontrolling Interests,2024-03-31 00:00:00,1715900000.0,AARTIDRUGS.NS
Net Income Continuous Operations,2024-03-31 00:00:00,1715900000.0,AARTIDRUGS.NS
Tax Provision,2024-03-31 00:00:00,639400000.0,AARTIDRUGS.NS
Pretax Income,2024-03-31 00:00:00,2355300000.0,AARTIDRUGS.NS
Other Non Operating Income Expenses,2024-03-31 00:00:00,40300000.0,AARTIDRUGS.NS
Special Income Charges,2024-03-31 00:00:00,0.0,AARTIDRUGS.NS
Other Special Charges,2024-03-31 00:00:00,1834000.0,AARTIDRUGS.NS
Write Off,2024-03-31 00:00:00,21875000.0,AARTIDRUGS.NS
Net Non Operating Interest Income Expense,2024-03-31 00:00:00,-335200000.0,AARTIDRUGS.NS
Total Other Finance Cost,2024-03-31 00:00:00,43730000.0,AARTIDRUGS.NS
Interest Expense Non Operating,2024-03-31 00:00:00,335200000.0,AARTIDRUGS.NS
Interest Income Non Operating,2024-03-31 00:00:00,24955000.0,AARTIDRUGS.NS
Operating Income,2024-03-31 00:00:00,2650100000.0,AARTIDRUGS.NS
Operating Expense,2024-03-31 00:00:00,5858500000.0,AARTIDRUGS.NS
Other Operating Expenses,2024-03-31 00:00:00,4320600000.0,AARTIDRUGS.NS
Depreciation And Amortization In Income Statement,2024-03-31 00:00:00,514500000.0,AARTIDRUGS.NS
Amortization,2024-03-31 00:00:00,3989000.0,AARTIDRUGS.NS
Depreciation Income Statement,2024-03-31 00:00:00,514500000.0,AARTIDRUGS.NS
Selling General And Administration,2024-03-31 00:00:00,718722000.0,AARTIDRUGS.NS
Selling And Marketing Expense,2024-03-31 00:00:00,576887000.0,AARTIDRUGS.NS
General And Administrative Expense,2024-03-31 00:00:00,141835000.0,AARTIDRUGS.NS
Gross Profit,2024-03-31 00:00:00,8508600000.0,AARTIDRUGS.NS
Cost Of Revenue,2024-03-31 00:00:00,16777200000.0,AARTIDRUGS.NS
Total Revenue,2024-03-31 00:00:00,25285800000.0,AARTIDRUGS.NS
Operating Revenue,2024-03-31 00:00:00,25285800000.0,AARTIDRUGS.NS
Tax Effect Of Unusual Items,2023-03-31 00:00:00,-3947159.5,AARTIDRUGS.NS
Tax Rate For Calcs,2023-03-31 00:00:00,0.2579,AARTIDRUGS.NS
Normalized EBITDA,2023-03-31 00:00:00,3093300000.0,AARTIDRUGS.NS
Total Unusual Items,2023-03-31 00:00:00,-15305000.0,AARTIDRUGS.NS
Total Unusual Items Excluding Goodwill,2023-03-31 00:00:00,-15305000.0,AARTIDRUGS.NS
Net Income From Continuing Operation Net Minority Interest,2023-03-31 00:00:00,1663088000.0,AARTIDRUGS.NS
Reconciled Depreciation,2023-03-31 00:00:00,503241000.0,AARTIDRUGS.NS
Reconciled Cost Of Revenue,2023-03-31 00:00:00,22225987000.0,AARTIDRUGS.NS
EBITDA,2023-03-31 00:00:00,3077995000.0,AARTIDRUGS.NS
EBIT,2023-03-31 00:00:00,2574753000.0,AARTIDRUGS.NS
Net Interest Income,2023-03-31 00:00:00,-364388000.0,AARTIDRUGS.NS
Interest Expense,2023-03-31 00:00:00,332932000.0,AARTIDRUGS.NS
Interest Income,2023-03-31 00:00:00,6992000.0,AARTIDRUGS.NS
Normalized Income,2023-03-31 00:00:00,1674445840.5,AARTIDRUGS.NS
Net Income From Continuing And Discontinued Operation,2023-03-31 00:00:00,1663088000.0,AARTIDRUGS.NS
Total Expenses,2023-03-31 00:00:00,24392183000.0,AARTIDRUGS.NS
Rent Expense Supplemental,2023-03-31 00:00:00,600000.0,AARTIDRUGS.NS
Diluted Average Shares,2023-03-31 00:00:00,92600000.0,AARTIDRUGS.NS
Basic Average Shares,2023-03-31 00:00:00,92600000.0,AARTIDRUGS.NS
Diluted EPS,2023-03-31 00:00:00,17.97,AARTIDRUGS.NS
Basic EPS,2023-03-31 00:00:00,17.97,AARTIDRUGS.NS
Diluted NI Availto Com Stockholders,2023-03-31 00:00:00,1663088000.0,AARTIDRUGS.NS
Net Income Common Stockholders,2023-03-31 00:00:00,1663088000.0,AARTIDRUGS.NS
Otherunder Preferred Stock Dividend,2023-03-31 00:00:00,0.0,AARTIDRUGS.NS
Net Income,2023-03-31 00:00:00,1663088000.0,AARTIDRUGS.NS
Minority Interests,2023-03-31 00:00:00,-484000.0,AARTIDRUGS.NS
Net Income Including Noncontrolling Interests,2023-03-31 00:00:00,1663572000.0,AARTIDRUGS.NS
Net Income Continuous Operations,2023-03-31 00:00:00,1663572000.0,AARTIDRUGS.NS
Tax Provision,2023-03-31 00:00:00,578249000.0,AARTIDRUGS.NS
Pretax Income,2023-03-31 00:00:00,2241821000.0,AARTIDRUGS.NS
Other Non Operating Income Expenses,2023-03-31 00:00:00,-42003000.0,AARTIDRUGS.NS
Special Income Charges,2023-03-31 00:00:00,-15305000.0,AARTIDRUGS.NS
Other Special Charges,2023-03-31 00:00:00,,AARTIDRUGS.NS
Write Off,2023-03-31 00:00:00,15305000.0,AARTIDRUGS.NS
Net Non Operating Interest Income Expense,2023-03-31 00:00:00,-364388000.0,AARTIDRUGS.NS
Total Other Finance Cost,2023-03-31 00:00:00,38448000.0,AARTIDRUGS.NS
Interest Expense Non Operating,2023-03-31 00:00:00,332932000.0,AARTIDRUGS.NS
Interest Income Non Operating,2023-03-31 00:00:00,6992000.0,AARTIDRUGS.NS
Operating Income,2023-03-31 00:00:00,2663495000.0,AARTIDRUGS.NS
Operating Expense,2023-03-31 00:00:00,2166196000.0,AARTIDRUGS.NS
Other Operating Expenses,2023-03-31 00:00:00,6239000.0,AARTIDRUGS.NS
Depreciation And Amortization In Income Statement,2023-03-31 00:00:00,503242000.0,AARTIDRUGS.NS
Amortization,2023-03-31 00:00:00,648000.0,AARTIDRUGS.NS
Depreciation Income Statement,2023-03-31 00:00:00,502594000.0,AARTIDRUGS.NS
Selling General And Administration,2023-03-31 00:00:00,835934000.0,AARTIDRUGS.NS
Selling And Marketing Expense,2023-03-31 00:00:00,698067000.0,AARTIDRUGS.NS
General And Administrative Expense,2023-03-31 00:00:00,137867000.0,AARTIDRUGS.NS
Gross Profit,2023-03-31 00:00:00,4829691000.0,AARTIDRUGS.NS
Cost Of Revenue,2023-03-31 00:00:00,22225987000.0,AARTIDRUGS.NS
Total Revenue,2023-03-31 00:00:00,27055678000.0,AARTIDRUGS.NS
Operating Revenue,2023-03-31 00:00:00,27055678000.0,AARTIDRUGS.NS
Tax Effect Of Unusual Items,2022-03-31 00:00:00,-4057719.0,AARTIDRUGS.NS
Tax Rate For Calcs,2022-03-31 00:00:00,0.2406,AARTIDRUGS.NS
Normalized EBITDA,2022-03-31 00:00:00,3424385000.0,AARTIDRUGS.NS
Total Unusual Items,2022-03-31 00:00:00,-16865000.0,AARTIDRUGS.NS
Total Unusual Items Excluding Goodwill,2022-03-31 00:00:00,-16865000.0,AARTIDRUGS.NS
Net Income From Continuing Operation Net Minority Interest,2022-03-31 00:00:00,2050386000.0,AARTIDRUGS.NS
Reconciled Depreciation,2022-03-31 00:00:00,500489000.0,AARTIDRUGS.NS
Reconciled Cost Of Revenue,2022-03-31 00:00:00,19849832000.0,AARTIDRUGS.NS
EBITDA,2022-03-31 00:00:00,3407520000.0,AARTIDRUGS.NS
EBIT,2022-03-31 00:00:00,2907031000.0,AARTIDRUGS.NS
Net Interest Income,2022-03-31 00:00:00,-231909000.0,AARTIDRUGS.NS
Interest Expense,2022-03-31 00:00:00,207480000.0,AARTIDRUGS.NS
Interest Income,2022-03-31 00:00:00,7169000.0,AARTIDRUGS.NS
Normalized Income,2022-03-31 00:00:00,2063193281.0,AARTIDRUGS.NS
Net Income From Continuing And Discontinued Operation,2022-03-31 00:00:00,2050386000.0,AARTIDRUGS.NS
Total Expenses,2022-03-31 00:00:00,21908489000.0,AARTIDRUGS.NS
Rent Expense Supplemental,2022-03-31 00:00:00,600000.0,AARTIDRUGS.NS
Diluted Average Shares,2022-03-31 00:00:00,92600000.0,AARTIDRUGS.NS
Basic Average Shares,2022-03-31 00:00:00,92600000.0,AARTIDRUGS.NS
Diluted EPS,2022-03-31 00:00:00,22.142397,AARTIDRUGS.NS
Basic EPS,2022-03-31 00:00:00,22.142397,AARTIDRUGS.NS
Diluted NI Availto Com Stockholders,2022-03-31 00:00:00,2050386000.0,AARTIDRUGS.NS
Net Income Common Stockholders,2022-03-31 00:00:00,2050386000.0,AARTIDRUGS.NS
Otherunder Preferred Stock Dividend,2022-03-31 00:00:00,0.0,AARTIDRUGS.NS
Net Income,2022-03-31 00:00:00,2050386000.0,AARTIDRUGS.NS
Minority Interests,2022-03-31 00:00:00,428000.0,AARTIDRUGS.NS
Net Income Including Noncontrolling Interests,2022-03-31 00:00:00,2049958000.0,AARTIDRUGS.NS
Net Income Continuous Operations,2022-03-31 00:00:00,2049958000.0,AARTIDRUGS.NS
Tax Provision,2022-03-31 00:00:00,649593000.0,AARTIDRUGS.NS
Pretax Income,2022-03-31 00:00:00,2699551000.0,AARTIDRUGS.NS
Other Non Operating Income Expenses,2022-03-31 00:00:00,-45632000.0,AARTIDRUGS.NS
Special Income Charges,2022-03-31 00:00:00,-16865000.0,AARTIDRUGS.NS
Other Special Charges,2022-03-31 00:00:00,,AARTIDRUGS.NS
Write Off,2022-03-31 00:00:00,16865000.0,AARTIDRUGS.NS
Net Non Operating Interest Income Expense,2022-03-31 00:00:00,-231909000.0,AARTIDRUGS.NS
Total Other Finance Cost,2022-03-31 00:00:00,31598000.0,AARTIDRUGS.NS
Interest Expense Non Operating,2022-03-31 00:00:00,207480000.0,AARTIDRUGS.NS
Interest Income Non Operating,2022-03-31 00:00:00,7169000.0,AARTIDRUGS.NS
Operating Income,2022-03-31 00:00:00,2977969000.0,AARTIDRUGS.NS
Operating Expense,2022-03-31 00:00:00,2058657000.0,AARTIDRUGS.NS
Other Operating Expenses,2022-03-31 00:00:00,3226000.0,AARTIDRUGS.NS
Depreciation And Amortization In Income Statement,2022-03-31 00:00:00,500489000.0,AARTIDRUGS.NS
Amortization,2022-03-31 00:00:00,407000.0,AARTIDRUGS.NS
Depreciation Income Statement,2022-03-31 00:00:00,500082000.0,AARTIDRUGS.NS
Selling General And Administration,2022-03-31 00:00:00,815937000.0,AARTIDRUGS.NS
Selling And Marketing Expense,2022-03-31 00:00:00,683648000.0,AARTIDRUGS.NS
General And Administrative Expense,2022-03-31 00:00:00,132289000.0,AARTIDRUGS.NS
Gross Profit,2022-03-31 00:00:00,5036626000.0,AARTIDRUGS.NS
Cost Of Revenue,2022-03-31 00:00:00,19849832000.0,AARTIDRUGS.NS
Total Revenue,2022-03-31 00:00:00,24886458000.0,AARTIDRUGS.NS
Operating Revenue,2022-03-31 00:00:00,24886458000.0,AARTIDRUGS.NS
Tax Effect Of Unusual Items,2021-03-31 00:00:00,,AARTIDRUGS.NS
Tax Rate For Calcs,2021-03-31 00:00:00,,AARTIDRUGS.NS
Normalized EBITDA,2021-03-31 00:00:00,,AARTIDRUGS.NS
Total Unusual Items,2021-03-31 00:00:00,,AARTIDRUGS.NS
Total Unusual Items Excluding Goodwill,2021-03-31 00:00:00,,AARTIDRUGS.NS
Net Income From Continuing Operation Net Minority Interest,2021-03-31 00:00:00,,AARTIDRUGS.NS
Reconciled Depreciation,2021-03-31 00:00:00,,AARTIDRUGS.NS
Reconciled Cost Of Revenue,2021-03-31 00:00:00,,AARTIDRUGS.NS
EBITDA,2021-03-31 00:00:00,,AARTIDRUGS.NS
EBIT,2021-03-31 00:00:00,,AARTIDRUGS.NS
Net Interest Income,2021-03-31 00:00:00,,AARTIDRUGS.NS
Interest Expense,2021-03-31 00:00:00,,AARTIDRUGS.NS
Interest Income,2021-03-31 00:00:00,25958000.0,AARTIDRUGS.NS
Normalized Income,2021-03-31 00:00:00,,AARTIDRUGS.NS
Net Income From Continuing And Discontinued Operation,2021-03-31 00:00:00,,AARTIDRUGS.NS
Total Expenses,2021-03-31 00:00:00,,AARTIDRUGS.NS
Rent Expense Supplemental,2021-03-31 00:00:00,600000.0,AARTIDRUGS.NS
Diluted Average Shares,2021-03-31 00:00:00,,AARTIDRUGS.NS
Basic Average Shares,2021-03-31 00:00:00,,AARTIDRUGS.NS
Diluted EPS,2021-03-31 00:00:00,,AARTIDRUGS.NS
Basic EPS,2021-03-31 00:00:00,,AARTIDRUGS.NS
Diluted NI Availto Com Stockholders,2021-03-31 00:00:00,,AARTIDRUGS.NS
Net Income Common Stockholders,2021-03-31 00:00:00,,AARTIDRUGS.NS
Otherunder Preferred Stock Dividend,2021-03-31 00:00:00,,AARTIDRUGS.NS
Net Income,2021-03-31 00:00:00,,AARTIDRUGS.NS
Minority Interests,2021-03-31 00:00:00,,AARTIDRUGS.NS
Net Income Including Noncontrolling Interests,2021-03-31 00:00:00,,AARTIDRUGS.NS
Net Income Continuous Operations,2021-03-31 00:00:00,,AARTIDRUGS.NS
Tax Provision,2021-03-31 00:00:00,,AARTIDRUGS.NS
Pretax Income,2021-03-31 00:00:00,,AARTIDRUGS.NS
Other Non Operating Income Expenses,2021-03-31 00:00:00,,AARTIDRUGS.NS
Special Income Charges,2021-03-31 00:00:00,,AARTIDRUGS.NS
Other Special Charges,2021-03-31 00:00:00,-32668000.0,AARTIDRUGS.NS
Write Off,2021-03-31 00:00:00,38887000.0,AARTIDRUGS.NS
Net Non Operating Interest Income Expense,2021-03-31 00:00:00,,AARTIDRUGS.NS
Total Other Finance Cost,2021-03-31 00:00:00,32733000.0,AARTIDRUGS.NS
Interest Expense Non Operating,2021-03-31 00:00:00,,AARTIDRUGS.NS
Interest Income Non Operating,2021-03-31 00:00:00,25958000.0,AARTIDRUGS.NS
Operating Income,2021-03-31 00:00:00,,AARTIDRUGS.NS
Operating Expense,2021-03-31 00:00:00,,AARTIDRUGS.NS
Other Operating Expenses,2021-03-31 00:00:00,,AARTIDRUGS.NS
Depreciation And Amortization In Income Statement,2021-03-31 00:00:00,,AARTIDRUGS.NS
Amortization,2021-03-31 00:00:00,11755000.0,AARTIDRUGS.NS
Depreciation Income Statement,2021-03-31 00:00:00,,AARTIDRUGS.NS
Selling General And Administration,2021-03-31 00:00:00,744591000.0,AARTIDRUGS.NS
Selling And Marketing Expense,2021-03-31 00:00:00,650196000.0,AARTIDRUGS.NS
General And Administrative Expense,2021-03-31 00:00:00,94395000.0,AARTIDRUGS.NS
Gross Profit,2021-03-31 00:00:00,,AARTIDRUGS.NS
Cost Of Revenue,2021-03-31 00:00:00,,AARTIDRUGS.NS
Total Revenue,2021-03-31 00:00:00,,AARTIDRUGS.NS
Operating Revenue,2021-03-31 00:00:00,,AARTIDRUGS.NS
